Gilead data suggests coronavirus patients respond to treatment


A Chicago Hospital Treating Severe Covid-19 Patients With Remedivir, An Antiviral Drug From Gilead Sciences In A Closely Monitored Clinical Trial, Experiences Rapid Recovery From Fever And Respiratory Symptoms, With Almost All Patients Coming Out a week, learned STAT.

Remdesivir was one of the first drugs identified as having an impact on SARS-CoV-2, the new coronavirus that causes Covid-19, in laboratory tests. The world is awaiting the results of Gilead’s clinical trials, and positive results would likely lead to quick approvals by the Food and Drug Administration and other regulatory agencies. If it is safe and effective, it could become the first approved treatment for the disease.

The University of Chicago Medicine recruited 125 people with Covid-19 in two Gilead phase 3 clinical trials. Among these people, 113 suffered from a serious illness. All patients were treated with daily infusions of remdesivir.



Please enter your comment!
Please enter your name here